{"id":"shr-1918-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL4303507","moleculeType":"Small molecule","molecularWeight":"286.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking PD-1, SHR-1918 relieves immune checkpoint inhibition and activates T cells. Simultaneously, it neutralizes TGF-β, a key immunosuppressive cytokine in the tumor microenvironment, further enhancing T-cell infiltration and anti-tumor activity. This dual mechanism addresses two major immune evasion pathways in cancer.","oneSentence":"SHR-1918 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:28.551Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT07308392","phase":"PHASE2","title":"Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis","status":"RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2026-02-25","conditions":"Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis","enrollment":108},{"nctId":"NCT07404553","phase":"PHASE2, PHASE3","title":"A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2026-03","conditions":"Hypercholesterolemia","enrollment":126},{"nctId":"NCT07349615","phase":"PHASE3","title":"A Study of SHR-1918 In Participants With Hypertriglyceridemia","status":"NOT_YET_RECRUITING","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2026-02","conditions":"Hypertriglyceridemia","enrollment":360},{"nctId":"NCT06471218","phase":"PHASE2","title":"Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2024-07-02","conditions":"Hyperlipidemia","enrollment":44},{"nctId":"NCT05432544","phase":"PHASE1","title":"Safety and Tolerability of SHR-1918 in Healthy Subjects","status":"UNKNOWN","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2022-06-27","conditions":"Hyperlipemia","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-1918 Injection","genericName":"SHR-1918 Injection","companyName":"Beijing Suncadia Pharmaceuticals Co., Ltd","companyId":"beijing-suncadia-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1918 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}